VEGFA and myasthenia gravis: However, quantitative analyses of mechanistic differences between the two types of responses are needed to elucidate VEGF mechanism(s) of action on MG behaviors [62,63], as the delivery, dosage, and duration of anti-VEGF pharmacology may bypass and/or alter innate, neuroprotective responses of MG.